Relationship Between Sonic Hedgehog Protein, Brain-Derived Neurotrophic Factor and Oxidative Stress in Autism Spectrum Disorders by Al-Ayadhi, Laila Y.
ORIGINAL PAPER
Relationship Between Sonic Hedgehog Protein, Brain-Derived
Neurotrophic Factor and Oxidative Stress in Autism Spectrum
Disorders
Laila Y. Al-Ayadhi
Received: 19 August 2011/Revised: 27 September 2011/Accepted: 29 September 2011/Published online: 9 October 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract The etiology of autism spectrum disorders
(ASD) is not well known but oxidative stress has been
suggested to play a pathological role. We report here that
the serum levels of Sonic hedgehog (SHH) protein and
brain-derived neurotrophic factor (BDNF) might be linked
to oxidative stress in ASD. By using the whole blood
or polymorphonuclear leukocytes, we demonstrated that
autistic children produced a signiﬁcantly higher level of
oxygen free radicals (OFR). In addition, we found signif-
icantly higher levels of serum SHH protein in children with
mild as well as severe form of autism. We also found that
the serum level of BDNF was signiﬁcantly reduced in
autistic children with mild form of the disorder but not with
severe form of the disorder. Our ﬁndings are the ﬁrst to
report a correlation between SHH, BDNF and OFR in
autistic children, suggesting a pathological role of oxida-
tive stress and SHH in autism spectrum disorders.
Keywords Autism spectrum disorders  Sonic hedgehog 
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Introduction
Autism spectrum disorders (ASD) refer to a broad spec-
trum of neurodevelopmental disorders known as pervasive
developmental disorders (PDD), including autism,
Asperger’s syndrome, Rett’s syndrome, and childhood
disintegrative disorder. By deﬁnition, ASD are character-
ized by impairments in verbal and nonverbal communica-
tion and social interaction [1], with onset usually occurring
around the ﬁrst 36 months of childhood. Repetitive, ste-
reotyped, purposeless behaviors as well as attention and
sensory dysfunctions are common ﬁndings in patients with
ASD. In recent years, the prevalence of ASD has increased
dramatically, and this increase, cannot be attributed com-
pletely to improved diagnostic techniques and increased
awareness only [2]. Latest reports estimate that ASD
affects approximately one in every hundred children, with a
male-to-female ratio of four to one (4:1) [2]. Despite that
the fact that there is an increase in autism research
worldwide, exact etiology of autism and ASD remains
largely unknown.
Itiswellknownthatoxidativestressresultingfromexcess
generation of reactive-oxygen species (ROS) is a major
contributing factor in neurodegenerative diseases such as
Parkinson’s disease, Alzheimer’s disease and ASD [3].
Sonic hedgehog (SHH) protein is a signaling protein from
the Hedgehog family. When SHH binds to its receptor Pat-
ched-1 (PTCH1), PTCH1 cannot interact with the trans-
membraneproteinSmoothened(SMO),resultinginactivation
of transcription factor GLI. The activated GLI regulates
expression of many target genes that control cell growth,
survival, and differentiation in a wide variety of cells,
including neurons [4]. SHH signaling is vital during embry-
onic development. Previous studies have demonstrated that
SHHsignalingisactivatedinadultorganismafterinjuryandis
involved in tissue repair mechanisms [4, 5].
Activation of SHH pathway up-regulates two neurotro-
phic factors, namely vascular endothelial growth factor
(VEGF) and brain-derived neurotrophic factor (BDNF). As
a result, activation of SHH signaling protects cortical
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posal of a potential role of SHH for the clinical treatments
of brain ischemia and neurodegenerative disorders [6].
Thus the aim of the present study was to explore the
relationship of SHH pathway, oxidative stress and BDNF
in children with ASD.
Materials and Methods
Patients and Subjects
Forty-four children with ASD were recruited in the study
(41 males and 3 females) ranging in age from 3 to 9 years
and 40 age- and sex- matched healthy children (38 males
and 2 females) served as the control group. The diagnosis
of autism was made by child neurophysiologist, and pedi-
atrician based on the criteria of autistic disorder as deﬁned
in the DSM-IV, CARS. Complete diagnostic work-ups
including medical, neurological, psychiatric, and psycho-
logical evaluations were done for all of the subjects. All
were in good physical health and were not taking any
medications or nutrient supplements. Written consent was
obtained from the parents of each subject, according to the
guidelines of the ethical committee of King Khalid Hos-
pital, King Saud University, Riyadh, Saudi Arabia.
Blood Samples
After an overnight fasting, blood samples (10 ml) were
collected from children in both groups in plain test tubes.
Blood samples were centrifuged at 3,000 rpm to collect
serum samples, which were stored frozen in a freezer at
-80C until the time of analytical assays.
SHH Assay
Serum level of SHH was measured using a commercially
available sandwich enzyme immunoassay (ELISA) kit
from CUSABIO BIOTECH CO. Ltd (Wuhan, China).
BDNF Assay
Serum level of BDNF was measured using a commercially
available sandwich enzyme immunoassay (ELISA) kit
from Emax Immunoassay System (Promega Corp., Madi-
son, Wisconsin).
Blood PMNL Isolation
Polymorphonuclear leukocytes (PMNL) were separated
by using PMNL isolation medium (Robbins Scientiﬁc
Corporation, Sunnyvale, CA). Five to seven milliliter of
heparinized blood was layered over 4 ml of PMNL-Isola-
tion Medium in a 15 ml tube and then centrifuged at
4009g for 30 min at room temperature. The leukocyte-rich
plasma was carefully removed with a Pasteur pipette
and transferred to a 15 ml conical centrifuge tube, ﬁlled
with phosphate buffered saline (PBS) and centrifuged at
3509g for 10 min (Jouan centrifuge Model B4i, France).
Two milliliter of lysing buffer (0.87% NH4Cl) were added
to lyse residual erythrocytes and the cell suspension was,
centrifuged at 2509g for 10 min. The supernatant was
discarded and the pellet was resuspended in 1 ml of 5%
fetal calf serum (FCS). A cell count taken that was then
to a desired ﬁnal concentration [7, 8]. Cell viability was
determined by trypan blue (0.2%) exclusion method [7, 8].
Chemiluminescence Assay and Oxygen Free Radicals
Measurement: Luminol-Enhanced Chemiluminescence
A Berthold (AutoLumatPlus LB 953) luminometer with a
constant temperature (37C) controller (Bethold Technol-
ogies GmbH & Co. KG, Calmbacher Strabe 22, D-75323
Bad Wildbad-Germany) connected to a computer was used.
The reaction mixture consisted of 100 ll of whole blood or
PMNLs suspension and 900 ll medium containing 10
-5M
luminol (5-amino-2,3-dihydro,1,4-phthalazinedione Sigma
Chemical Co., St. Louis, MO, USA), 2 ng/ml phorbol
myristate acetate (PMA) Sigma Chemical Co., St. Louis,
MO, USA, 1.25 mg/ml opsonized zymosan (OPZ) Sigma
Chemical Co., St. Louis, MO, USA and phosphate buffered
saline (PBS). Whole blood or PMNLs suspension, trig-
gered by adding prepared PMA or OPZ solution. Light
emission was recorded in millivolts (mV) and the readings
were recorded at 1 min intervals for 30 min. CL emission
was quantiﬁed as the peak height in mV [7, 8].
Statistical Analysis
Metabolic data are presented as means ± standard devia-
tion (SD). Statistical differences were ascertained by using
the Student’s t test with signiﬁcance set at a P value of 0.05
or lower.
Results
The results of the respiratory burst of whole blood and
PMNLs from autistic and control subjects are shown in
Tables 1, 2, 3 and 4. The respiratory burst of whole blood
stimulated with PMA and OPZ, autistic (males and
females) were signiﬁcantly higher (P\0.05) compared to
control children (Tables 1 and 2). This increase was not
related to the severity of the disorder. Similar ﬁndings were
Neurochem Res (2012) 37:394–400 395
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and control children (Tables 3 and 4) and the increase was
not related to the severity of the disorder.
Furthermore, BDNF serum level were signiﬁcantly
higher in mild autistic children compared to age and sex
matched control subjects (442 ± 20 (pg.ml), 290 ± 90
(pg/ml), P\0.05), respectively. On the other hand, serum
level of BDNF, was not statistically signiﬁcant in severe
autism as compared to age and sex matched control/sub-
jects (323 ± 114 (pg/ml), 290 ± 90 (pg/ml), P[0.05)
respectively, Fig. 1. In addition, Sonic hedgehog serum
level were very highly statistically signiﬁcant in mild
(10.4 ± 3 (pg/ml)) and severe autism (24.2 ± 6 (pg/ml))
compared to control (2.6 ± 2 (pg/ml)) P\0.0001), Fig. 2.
In addition, the level of SHH were positively correlated
with the severity of autism (r = 0.69) Fig. 3.
Table 1 Respiratory burst of whole blood stimulated by PMA, as measured by chemiluminescence (CL), in control and children with ASD
Subjects participated (n = no. of subjects) CL measurement (mV)
Basal Maximum peak (mV) Time to peak (min)
Control
Male (n = 38) 0.90 ± 0.6 10 ± 4 1,800 ± 53
Female (n = 2) 0.92 ± 0.7 12 ± 6 1,721 ± 65
Autistic
Male (n = 41) 1.81 ± 0.5 24.13 ± 2* 1,960 ± 70
Female (n = 3) 1.5 ± 0.3 23.7 ± 6* 1,720 ± 21
PMA concentration = 2 lg/cuvete; Luminol concentration = 2M
4/cuvete; Values are expressed as mean ± SD
* P\0.05 (as compared to control group)
Table 2 Respiratory burst of whole blood stimulated by OPZ, as measured by chemiluminescence (CL), in control and children with ASD
Subjects participated (n = no. of subjects) CL measurement (mV)
Basal Maximum peak (mV) Time to peak (min)
Control
Male (n = 38) 0.90 ± 0.6 10 ± 4 2,216 ± 65
Female (n = 2) 0.92 ± 0.7 12 ± 6 2,310 ± 54
Autistic
Male (n = 41) 1.81 ± 0.5 24.13 ± 2* 3,258 ± 76
Female (n = 3) 1.5 ± 0.3 23.7 ± 6* 3,174 ± 62
OPZ concentration = 200 lg/ml; Luminol concentration = 2M
4/cuvete; Values are expressed as mean ± SD
* P\0.05 (as compared to control group)
Table 3 Respiratory burst of polymorphoneuclear leukocytes (PMNLs), stimulated by PMA, as measured by chemiluminescence (CL) in
control and children with ASD
Subjects participated (n = no. of subjects) CL measurement (mV)
Basal Maximum peak (mV) Time to peak (min)
Control
Male (n = 38) 17.32 ± 6 303 ± 34 728 ± 35
Female (n = 2) 18.43 ± 1.5 298 ± 26 875 ± 42
Autistic
Male (n = 41) 31.8 ± 3 378 ± 51* 593 ± 54
Female (n = 3) 29.7 ± 4 412 ± 41* 643 ± 75
PMA concentration = 2 lg/cuvete; Luminol concentration = 2M
4/cuvete; Values are expressed as mean ± SD
* P\0.05 (as compared to control group)
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The etiology of ASD is not well understood, though it
likely involves genetic, immunologic, and environmental
factors [9]. The dramatic increase in reported prevalence
has encouraged an intense effort to identify early biological
markers [10]. Such markers could allow for earlier iden-
tiﬁcation and therapeutic intervention, contributing to
improved prognosis [11]. In the current study, we specu-
lated an important connection between SHH, BDNF path-
ways and oxidative stress. In our study, we demonstrated
statistically signiﬁcant increase in free radicals production
(superoxide anion (O2) hydrogen peroxide (H2O2), and
hydroxyl radicals (OH)), from whole blood and isolated
human PMNLs in autistic children when compared to age
and sex matched control. This increase was not related to
the degree of autism, or to the age of affected child. In
Table 4 Respiratory burst of polymorphoneuclear leukocytes (PMNLs), stimulated by OPZ, as measured by chemiluminescence (CL) in control
and children with ASD
Subjects participated (n = no. of subjects) CL measurement (mV)
Basal Maximum peak (mV) Time to peak (min)
Control
Male (28) 17.32 ± 6 303 ± 34 2,206 ± 45
Female (18) 18.43 ± 1.5 298 ± 26 2,234 ± 54
Autistic
Male (35) 31.8 ± 3 378 ± 51* 1,713 ± 64
Female (5) 29.7 ± 4 412 ± 41* 1,905 ± 54
OPZ concentration = 200 lg/ml; Luminol concentration = 2M
4/cuvete; Values are expressed as mean ± SD
* P\0.05 (as compared to control group)
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Fig. 1 Serum levels of BDNF in control and autistic children. BDNF
in mild and severe ASD, compared to control subject. BDNF serum
level were signiﬁcantly high in mild but not severe autistic children
compared to age and sex matched subjects 442 ± 20 (pg/ml),
290 ± 90 (pg/ml), P\0.05), respectively
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Fig. 2 Serum levels of Sonic hedgehog protein in control and autistic
children. Highly statistically signiﬁcant Sonic hedgehog serum level
in mild and severe autism
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Fig. 3 Relationship between SHH serum level and CARS score.
Serum Level of SHH protein was positively correlated with the
severity of autism (r = 0.69)
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123addition, we demonstrated higher serum level of SHH
concentration, which was positively correlated with the
degree of autism. Furthermore, we found a statistically
signiﬁcant higher level of BDNF in mild but not in sever
autism.
Oxidative stress is a process caused by exposure to
reactive oxygen intermediates, such as superoxide anion
(O2
-) hydrogen peroxide (H2O2), hydroxyl radicals (OH)
and nitric oxide (NO) which can damage proteins, nucleic
acids and cell membranes. The ROS within the cells are
neutralized by antioxidant defense mechanisms. SOD,
catalase and glutathione peroxidase (GPx) are the primary
enzymes involved in direct elimination of ROS, whereas
glutathione reductase and glucose-6-phosphate dehydro-
genase are secondary antioxidant enzymes, which help in
maintaining a steady concentration of glutathione and
NADPH necessary for optimal functioning of the primary
antioxidant enzymes [12–15]. Under normal conditions, a
dynamic equilibrium exists between the production of
reactive oxygen species (ROS) and the antioxidant capacity
of the cell [16, 17]. In pathological conditions, over pro-
duction of OFR or less effective antioxidant enzymatic
system, takes place, resulting in OFR overﬂow which leads
to tissue damage. Oxidative stress is an important mecha-
nism involved in brain damages, as consequences of
exposure to reactive oxygen species (ROS) [15, 17].
Brain-derived neurotrophic factor (BDNF) is a small
protein found throughout the central nervous system (CNS)
and peripheral blood. BDNF is the most widely distributed
neurotrophin in the CNS. BDNF plays a critical role in
axonal and dendritic growth and guidance. In addition,
BDNF participates in neurotransmitter release [18]. BDNF
is involved in the survival and differentiation of dopami-
nergic neurons in the developing brain [18, 19] and plays
an important role in the formation and plasticity of synaptic
connections [20].
Within the nervous system, SHH protein is associated
with development and patterning of the central nervous
system [5, 21, 22]. Latest reports have signiﬁed a critical
role played by SHH pathway in many neurological diseases.
However, its exact role and the underlying mechanisms are
still unclear. It has been reported that SHH expression is
up-regulated prior to the induction of BDNF mRNA, and
blocking SHH signals suppresses BDNF expression [23].
Considering the protective role of BDNF against oxidative
stress [24], therefore, activation of the SHH pathway
induces the increase of BDNF and results in neuroprotective
to oxidative stress. BDNF belongs to the neurotrophin
family that may affect neuronal survival and differentiation.
SHH is a morphogen important for the embryonic devel-
opment. Possible correlation between BDNF and SHH is
less well studied. Hashimoto and his colleagues in 2008,
demonstrated up-regulation of SHH expression, prior to the
induction of BDNF mRNA in Schwann cells adjacent to the
injured site in an animal model of sciatic nerve injury [23].
The same research group demonstrated causative relation-
ship between the induction of SHH and BDNF, continuous
administration of hedgehog inhibitor CPM to the injured
site suppressed the increase of BDNF expression and,
notably, deteriorated the survival of motor neurons in
lumbar spinal cord [23].
Wu et. al. [25], demonstrated BDNF-induced up-regu-
lation of SHH at both mRNA and protein levels, suggestive
of involvement of a transcriptional mechanism. Further-
more, the protective effect of BDNF was abolished by SHH
signaling inhibitor CPM. In addition, exogenous SHH-N
alone mimicked BDNF action that was sufﬁcient to atten-
uate 3-NP toxicity towards cortical neurons in a dose- and
time-dependent fashion [25]. Lately, a protective action
exerted by SHH has been revealed in several animal
models of ischemia/reperfusion [26]. In addition, pretreat-
ment of SHH has been shown to protect cardiomyocytes
against hydrogen peroxide-induced cytotoxicity in vitro
[27]. As a result, SHH may offer both anti oxidative and
anti-apoptotic actions under appropriate circumstances.
Metabolic stress induced by compromised mitochondria
has been implicated in both acute and chronic neurode-
generative disorders such as ischemic stroke, Alzheimer’s
disease, Parkinson’s disease (PD), and HD. It has also been
shown that SHH reduces behavioral deﬁcits induced by
intrastriatal 6 hydroxydopamine (6-OHDA) lesion and
suggests that SHH may be useful in the treatment of dis-
orders that affect the nigrostriatal system, such as PD [28].
Systemic administration of several neurotrophins such
as nerve growth factors and brain derived growth factor can
attenuate neuronal damage induced by chemical hypoxia in
vivo by a mechanism which may involve attenuation of
oxidative stress in neonatal rat model [29].
Normal SHH pathway was found to be necessary for
wound healing, and impaired coetaneous SHH signaling
pathway contributes to impaired NO function and wound
healing in diabetes. Delivery of exogenous SHH protein or
its receptor agonists may provide an effective means in
accelerating diabetic wound healing. Strategies aimed at
augmenting endogenous SHH pathway may provide an
effective means in ameliorating delayed diabetic wound
healing [30].
An increase in SHH protein was initially reported in the
gray matter from multiple sclerosis brains lesions [31]o ri n
animal models of this pathology including Experimental
Autoimmune Encepalomyelitis and cuprizone-induced
demyelination [32, 33]. The clinical improvement and
reduced demyelination driven by either interferon-b or
triiodothyronine in several rodent models of demyelinating
diseases are likely linked to an enhanced expression of
SHH [32, 33]. It points out towards a possible protective
398 Neurochem Res (2012) 37:394–400
123effect of exerted by SHH and it is with agreement to our
ﬁndings in autism. The most likely explanation for higher
level of SHH in autistic examined in this study is as a result
of increased oxygen free radicals production as a protective
mechanism secondary to increase oxidative stress inside
the autistic. The roles of the SHH signaling pathway in the
CNS are gaining some interest lately, due to a multifunc-
tional properties of SHH, ranging from the regulation of
new cells production to the modulation of neuronal elec-
trophysiological activity. The higher levels of OFR and
consequently SHH, demonstrated in the current study, in
mild ASD, resulted in an increase BDNF production as a
protective mechanism. In severe ASD the further increase
in OFR and SHH, produced a negative feed back response
on the production of BDNF, as demonstrated by lower
level of BDNF in severe but not in mild ASD. Existing data
provide support for considering SHH signaling as an
important mechanism in tissue-repair process in brain
diseases, and as a target for novel therapeutic approaches
for the treatment of brain disorders and in particular ASD.
Conclusion
The present study demonstrated the possible critical pro-
tective role played by SHH and BDNF in ASD, particularly
in relation to oxidative stress. Larger studies are strongly
recommended, to investigate the signiﬁcant role played by
BDNF in ASD phenotypes. Explanation of the underlying
molecular mechanism may help develop a novel thera-
peutic intervention for neuronal protection in ASD.
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